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Testosterone Therapy in
Women With Chronic Heart Failure
A Pilot Double-Blind, Randomized, Placebo-Controlled Study
Ferdinando Iellamo, MD,*† Maurizio Volterrani, MD,* Giuseppe Caminiti, MD,*
Roger Karam, MD,‡ Rosalba Massaro, MD,* Massimo Fini, MD,* Peter Collins, MD, PHD,*§
Giuseppe M. C. Rosano, MD*
Roma, Italy; Cinncinati, Ohio; and London, United Kingdom
Objectives The primary objective of this study was to assess the effect of a 6-month testosterone supplementation therapy
on functional capacity and insulin resistance in female patients with chronic heart failure (CHF).
Background Patients with CHF show decreased exercise capacity and insulin sensitivity. Testosterone supplementation im-
proves these variables in men with CHF. No study has evaluated the effects of testosterone supplementation on
female patients with CHF.
Methods Thirty-six elderly female patients with stable CHF, (ejection fraction 32.9  6) were randomly assigned (2:1 ra-
tio) to receive testosterone transdermal patch (T group, n  24) or placebo (P group, n  12), both on top of
optimal medical therapy. At baseline and after 6 months, patients underwent 6-min walking test (6MWT), car-
diopulmonary exercise test, echocardiogram, quadriceps maximal isometric voluntary contraction, dynamic
quadriceps isokinetic strength (peak torque), and insulin resistance assessment by homeostasis model.
Results Distance walked at 6MWT as well as peak oxygen consumption significantly improved in the T group, whereas
they were unchanged in the P group (p  0.05 for all comparisons). The homeostasis model was significantly
reduced in the T group in comparison with the P group (16.5% vs. 5%, respectively; p  0.05). Maximal
voluntary contraction and peak torque increased significantly in the T group but did not change in the P group.
Increase in distance walked at 6MWT was related to the increase in free testosterone levels (r  0.593,
p  0.01). No significant changes in echocardiographic parameters were observed in either group. No side
effects requiring discontinuation of T were detected.
Conclusions Testosterone supplementation improves functional capacity, insulin resistance, and muscle strength in women
with advanced CHF. Testosterone seems to be an effective and safe therapy for elderly women with CHF.
(J Am Coll Cardiol 2010;56:1310–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.090t
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ihronic heart failure (CHF) is a complex syndrome in
hich several pathophysiological mechanisms, in addition
o primary heart disease, are involved. Therapeutic strategies
argeted to the pathophysiological mechanisms sustaining
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010, accepted March 2, 2010.he progression and worsening of heart failure (HF), mainly
he prolonged neurohumoral activation, have been shown to
mprove quality of life and survival rate. Chronic heart
ailure is also characterized, in addition to neurohumoral
ctivation, by metabolic disorders including testosterone (T)
eficiency (1), insulin resistance (2), and a metabolic shift
avoring catabolism and impairment in skeletal muscle bulk
See page 1317
nd function, the latter being involved not only in symptoms
evelopment but even in the pathophysiology of the HF
yndrome (3). Low plasma levels of T have been reported in
atients with CHF (1,4,5), and it has been hypothesized
hat a relative hypotestosteronemia could be involved in the
mpairment of skeletal muscle function and exercise toler-
nce that occur in CHF (6). Indeed, anabolic hormone
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October 12, 2010:1310–6 Testosterone Therapy in Women With HFepletion is relatively common in CHF and would also carry
negative prognosis (7). Hence, improving the anabolic
tatus of patients with CHF could represent an additional
herapeutic target acting on a pathophysiological mecha-
ism that sustains the progression of the disease, possibly
ffecting survival (7). In keeping with this concept, several
tudies (6,8,9) and 1 recently by our group (10) reported
hat T supplementation given on top of optimal medical
herapy improved exercise capacity, ventilatory efficiency,
uscle strength, and insulin sensitivity in elderly men with
oderately severe CHF without major side effects.
Similar to the gradual decline of T observed with aging in
en, an age-dependent decline in endogenous total and free
occurs also in women (11), and in both sexes T therapy
ugments anabolic function, leading to increased muscle
ass and physical strength. In recent investigations, T
eplacement therapy at physiological levels increased muscle
ass and improved some cardiovascular risk factors, includ-
ng insulin resistance, in women with androgen deficiency
ue to hypopituitarism (12,13).
However, until now, the effects of T supplementation in
ost-menopausal elderly women with CHF have never been
ssessed.
Accordingly, the aim of this proof-of-concept study was
o assess the effects of low-dose T supplementation on
unctional capacity and insulin resistance in elderly women
ith moderate to severe HF. We also addressed the effect of
on quadriceps muscle performance to test the hypothesis
hat T supplementation could improve functional capacity
hrough an improvement of muscle performance.
ethods
atient population and study design. Patients were
creened and randomized between December 2006 and
ovember 2007, and the final patient completed the study
n April 2008. Patients were included in the study if they
ad symptomatic HF with functional New York Heart
ssociation functional class III, left ventricular ejection
raction 40%, and no hospital admission for HF in the
revious 3 months. Patients were excluded if they had
nstable angina or recent acute myocardial infarction, severe
iver or kidney diseases, neoplasias, post-menopausal hor-
one therapy, androgen therapy, bilateral oophorectomy, or
ysterectomy. From a total of 48 patients screened, 36 met
he inclusion criteria and were included in the study. Eight
atients were not included because of renal failure (creati-
ine clearance 30 mg/dl); 3 patients had hematocrit
50%; and 1 patient had undergone hysterectomy. All
atients gave written informed consent to participate in the
tudy, which was approved by the local ethics committee.
After the completion of baseline testing, patients were
andomly allocated in a 2:1 ratio to receive either transder-
al patch of T (300 g Intrinsa, Procter and Gamble,
incinnati, Ohio) or transdermal patch of placebo (P).
atches were applied twice/week to the abdominal skin setween 8:00 AM and 10:00 AM
or 24 weeks. Testosterone and P
ere dispensed by the Pharma-
ologic Department, which was
lso responsible for the random-
zation codes. Randomization
as blinded to investigators and
ubjects. Subjects returned for
ollow-up study visits 1 month
nd 3 and 6 months after base-
ine testing.
At baseline and at the end of
he study, patients underwent a
-min walking test (6MWT),
ardiopulmonary exercise test
CPET), echocardiographic ex-
mination, and muscle strength
ssessment. A blood sample was
rawn from an antecubital vein
fter an overnight fast for deter-
ination of serum hormones and
outine laboratory analyses. Se-
um T, free T, glucose, insulin, total cholesterol, high-
ensity lipoprotein cholesterol, triglycerides, alanine amino-
ransferase, aspartate aminotransferase, hemoglobin, and
reatinine were measured. Total T and sex hormone-
inding globulin (SHBG) were measured by chemilumines-
ent magnetic microparticle immunoassay (analytical sensi-
ivity 0.08 ng/ml and 0.1 nmol/l for T and SHBG,
espectively) with inter- and intra-assay variability coeffi-
ients of 8% and 5% for T and 10% and 5% for
HBG, respectively. Free T concentration was calculated
rom T and SHBG with the validated equation of Ver-
eulen et al. (14).
chocardiographic examination. A complete 2-dimensional,
-mode, and Doppler echocardiogram was performed at
aseline and at the end of the study by the same physicians
naware of clinical and study data, as previously described (10).
ssessment of functional capacity and cardiorespiratory
ndexes. Functional capacity was assessed by means of
MWT and CPET. The 6MWT was performed according
o standardized procedures (15). The CPET was performed
ith an electrically braked bicycle ergometer with monitor-
ng of gas exchange (Vmax 29 C, SensorMedics, Yorba
inda, California) as previously described (10) until exhaus-
ion. Peak oxygen consumption (VO2) was defined as the
ighest VO2 averaged for the last 30 s of exercise. Respi-
atory exchange ratio is calculated at the same time point. A
alue 1.10 was taken to represent adequate effort. The
entilation (VE)/carbon dioxide production (VCO2) slope,
hich relates the rate of increase in VE/unit increase in
arbon dioxide was calculated with the whole exercise
eriod. A 12-lead electrocardiogram was recorded continu-
usly, and blood pressure was measured every 2 min by a
Abbreviations
and Acronyms
6MWT  6-min walking
test
CHF  chronic heart failure
CPET  cardiopulmonary
exercise test
HF  heart failure
HOMA-IR  homeostasis
model assessment
MVC  maximal voluntary
contraction
P  placebo
SHBG  sex hormone-
binding globulin
T  testosterone
VE  ventilation
VCO2  carbon dioxide
production
VO2  oxygen consumptionphygmomanometer.
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Testosterone Therapy in Women With HF October 12, 2010:1310–6uscle performance assessment. Assessment of leg mus-
le strength was performed by means of a computer-based
ultifunctional dynamometer system (REV 9000, Techno-
ym, Gambettola, Italy) in the seated position. Muscle
trength was determined during both maximal isometric
maximal voluntary contraction [MVC]) and isokinetic
peak torque during dynamic leg flex-extension) effort, as
ecently described (10).
nsulin resistance. Glucose and insulin were measured
fter overnight fasting. The blood samples were collected in
-ml tubes, immediately placed on ice, and transferred to
he biochemistry laboratory where samples were processed.
lasma insulin levels were measured by immunoradiometric
ssay with a commercially available kit (DiaSorin, Inc.,
eutlinger, Germany). Insulin resistance was estimated by
he homeostasis model assessment (HOMA-IR) (16).
tatistical analysis. There were no studies on which to
alculate a power equation, because there are no previous
eports on the effects of T supplementation on the selected
nd points in women with CHF. We recently examined the
ffect of T replacement therapy in 70 CHF men and
eported a significant improvement in both 6MWT and
nsulin resistance as measured by HOMA-IR (10). On the
asis of that study, we estimated that a therapeutic effect
ould be demonstrated with 30 patients to obtain the same
ffect size, with 80% power and 5% significance assuming a
ropout rate of 10%.
Differences in baseline characteristics between treatment
nd P groups were evaluated by chi-square and unpaired
tests. Within-group changes in the reported variables were
valuated by paired t test or Wilcoxon signed rank test for
on-normally distributed variables. Between-groups com-
arisons were performed by unpaired t test and Mann-
hitney rank sum test (10). Relations between variables
ere assessed by Pearson product-moment correlation or
pearman’s rank test for non-normally distributed data
9,10). The primary end points were the treatment effect of
aseline Characteristics of Patients in the 2 GroupsTable 1 Baseline Characteristics of Patients in the 2 Groups
Testosterone
(n  20)
Placebo
(n  12)
Age, yrs 68.2 6.85 69.1 8.6
Diabetes 11 (55) 6 (50)
Hypertension 11 (55) 5 (42)
Dyslipidemia 13 (65) 8 (67)
Atrial fibrillation 6 (30) 3 (25)
Concomitant therapy
Beta-blockers 17 (85) 9 (75)
ACE inhibitors/ARBs 18 (90) 11 (92)
Diuretics 16 (80) 9 (75)
Aldosterone receptor blockers 12 (60) 7 (58)
Digoxin 6 (30) 4 (33)
Antiplatelet agents 20 (100) 12 (100)
Statins 17 (85) 8 (70)
o significant differences were found for any of the comparisons shown. Variables are reported ass
bsolute numbers and percentage, unless otherwise indicated.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker.versus P on the 6MWT distance in meters and insulin
esistance. Secondary end points were MVC and peak
orque.
Results are expressed as mean  SD. A 2-tailed p value
f 0.05 was considered significant. All analyses were
erformed with a commercially available statistical package
SPSS for Windows version 12.0, Chicago, Illinois).
esults
our patients in the T group discontinued the study after 1
o 2 months. The reason for discontinuation was in every
ase the willingness of the patient to escape from the study
e.g., logistic reasons and decision to discontinue the pro-
ocol not related to T supplementation).
Baseline characteristics of the patients are reported in
able 1. There were no significant differences between the
reatment and the P groups with respect to all variables.
The etiology of CHF was ischemic heart disease in all
ubjects. Patients were considered on top of medical therapy
Table 1), and medications were not altered throughout the
tudy.
At baseline, all patients had total T levels within the
ormal range (0.09 to 1.3 ng/ml); 13 patients (41%), 9 in
he treatment group and 4 in the P group, had free T levels
elow the normal range (0.9 to 4.0 pg/ml). Patients with
ow T levels (0.63  0.13 pg/ml) had a significantly lower
istance-walked at the 6MWT than patients with normal T
evels (226.5  41 m vs. 271.4  43 m, p  0.006), and
aseline free T levels correlated with distance walked in the
MWT (Fig. 1).
The effect of T supplementation on the different variables
s reported in Tables 2 and 3. Distance walked at the
MWT improved in both groups, but the increase in
MWT was significant only in patients under T supple-
entation. Peak VO2 significantly increased and VE/VCO2
Figure 1 Relation Between Free Testosterone Levels
and Distance Walked at 6MWT at Baseline
At baseline, there was a significant direct relationship between free
testosterone levels and the distance walked in the 6-min walking test (6MWT).lope significantly decreased in patients receiving T (n  13),
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October 12, 2010:1310–6 Testosterone Therapy in Women With HFhereas no significant changes in these variables were
etected in the P group (n  8). Seven patients in the T
roup and 4 in the P group did not complete CPET,
ecause they did not tolerate the mouth-piece/nose clip
pparatus. New York Heart Association functional class
mproved from III to II in 7 of 20 patients in the T group
nd in 2 of 12 in the P group (p  0.03). Total T and free
both increased with treatment but remained within the
ormal physiological range for post-menopausal women,
hereas no significant change was observed in the P group
Table 3).
The increase () in free T levels in the treatment group
as positively correlated with the increase in distance
alked at the 6MWT (r  0.593, p  0.01). The
mprovement in 6MWT in the treated group was greater in
atients with low as compared with normal baseline T levels
125.2  60.3 m vs. 68.8  53.1 m, p  0.05). The MVC
nd peak torque significantly improved in T-treated patients
ut remained unchanged in the P group (Table 2).
ardiorespiratory, Echocardiography, and Muscular Resultsefore and After 6 Months of Testosterone Supplementation TheraTable 2 Ca diorespir tory, Ech cardiography, and Muscular ReBefore and After 6 Months of Testosterone Supplemen
Testosterone Group
Before After
6MWT, m 260.6 52 357.2 43
Peak VO2, ml/kg/min 10.5 1.0 13.2 1.8
VE/VCO2 slope 34.6 5.0 31.1 7.0
SBP, mm Hg 115.2 18 113.8 23
DBP, mm Hg 79.2 9 80 7
Resting HR, beats/min 67.8 13 66.5 11
MVC, n 65.0 15 92.1 20
PTmax, Nm 41.3 17.4 74.2 14.8
EF, % 32.3 8.1 32.1 7.2
LVEDD, mm 62.7 12 63.5 13
ata are expressed as mean  SD. *Between-group differences at p  0.05.
DBP diastolic blood pressure; EF ejection fraction; HR heart rate; LVEDD left ventricular e
BP  systolic blood pressure; VCO2  carbon dioxide production; VE  ventilation; VO2  oxyge
etabolic and Hormonal Results Before and After 6 Months of TesTable 3 Metabolic and Hormonal Results Before and After 6 M
Testosterone Group
Before After
BMI, kg/m2 27.9 4.0 28.6 4.4
Body weight, kg 69.5 9.2 71.2 8.4
Fasting glycemia, mg/dl 109.3 26 106.2 31
Fasting insulinemia, U/ml 12.6 2.0 10.5 1.0
HOMA-IR 3.47 0.4 2.90 0.03
Total cholesterol, mg/dl 138.5 29 140.2 36
HDL cholesterol, mg/dl 31.3 7.1 36.0 5.7
Triglycerides, mg/dl 128.2 31 131.4 28
Free testosterone, pg/ml 0.95 0.4 2.2 0.8
Total testosterone, ng/ml 0.4 0.05 1.0 0.04
Hemoglobin, g/dl 11.0 2.3 12.7 2.4
Hematocrit, % 24.3 2.1 27.4 2.9
Creatinine, mg/dl 1.32 0.07 1.36 0.06ata are expressed as mean  SD. *Between-group differences at p  0.05.
BMI  body mass index; HDL  high-density lipoprotein; HOMA-IR  homeostasis model assessment.No significant changes in left ventricular ejection fraction,
eft ventricular end-diastolic diameter, heart rate, or systolic
nd diastolic blood pressure were detected in either group.
Metabolic and hormonal data are summarized in Table 3.
he HOMA-IR decreased significantly in the T group,
hereas it increased in the control group. High-density
ipoprotein cholesterol as well as hemoglobin level signifi-
antly increased in the T as compared with the P group. No
ignificant change in body weight or body mass index was
etected in either the T or the P groups.
Two patients in the T group discontinued the study, 1
ecause of generalized prurigo (without skin lesions), and
he other for her willingness to escape the study, the latter
eason being the same for discontinuation therapy in
patients in the P group. Discontinuation occurred
etween 3 and 6 months after baseline evaluation. No sign
f virilization was detected in the T group at intermediate
nd final visits, and patients did not report adverse effects
elated to T administration.
n Therapy
Placebo Group Changes ()
efore After Testosterone Placebo
9 39 291.3 22 96.6 14.5* 36.4 11.9
0 1.9 10.1 1.3 2.8 0.06* 0.1 0.03
8 6.0 34.2 8.4 3.5 0.1* 1.6 0.8
4 19 112.6 20 2.2 0.04 1.3 0.06
2 11 78.6 13 1.0 0.03 1.4. 0.04
6 11 68.0 13 1.3 0.05 0.6 0.02
4 14 69.9 16 27.1 4.7* 4.5 2.1
6 11.6 49.1 9.2 32.9 8.4* 5.5 1.2
8 7.3 31.5 7.7 0.2 0.03 0.3 0.07
9 13 62.4 11 0.8 0.05 0.5 0.02
tolic diameter; MVC isometric maximal voluntary contraction; PTmax isokinetic power torque;
mption; 6MWT  6-min walking test.
rone Supplementation Therapyof Testosterone Supplementation Therapy
Placebo Group Changes ()
efore After Testosterone Placebo
.8 3.7 27.9 3.6 0.7 0.04 0.1 0.03
.2 8.3 70.5 9.9 1.7 0.06 0.2 0.02
.1 4.3 111.6 27 3.1 0.4 2.5 0.2
.8 4.0 12.7 3.0 1.9 0.06* 0.9 0.02
2 0.07 3.49 0.04 0.57 0.03* 0.17 0.02
.5 42 143.0 48 1.7 0.05 2.5 0.2
.0 6.2 36.6 6.9 4.7 0.9 0.4 0.05
.1 30 124.3 32 3.2 0.3 3.6 0.1
3 0.2 0.65 0.3 1.2 0.04* 0.3 0.05
.4 0.07 0.3 0.08 0.6 0.05* 0.1 0.02
.7 2.7 10.2 3.1 1.7 0.06* 0.5 0.03
.7 2.4 25.2 2.6 3.1 0.2* 0.5 0.2
4 0.1 1.35 0.08 0.4 0.03 0.1 0.02pysults
tatio
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Testosterone Therapy in Women With HF October 12, 2010:1310–6During follow-up, 2 patients in the T group and 2 in the
group had worsening HF that was treated with increased
oses of diuretics. Six patients in the T group and 2 in the
group referred mild skin irritation in the site of the patch
pplication that did not require discontinuation of therapy.
iscussion
his is to our knowledge the first study to address the
otential benefits of T administration in women with CHF.
he results show that physiological T replacement therapy
mproves functional capacity and insulin resistance in
omen with CHF. The relevance of this finding should be
laced in the context of the established evidence indicating
he adverse prognostic role of low functional capacity and
nsulin resistance in patients with CHF.
Established evidence indicates that CHF is a syndrome
nvolving not only the failing heart, but also peripheral
keletal muscles as well as neurohumoral, endocrine, and
etabolic systems. These include a decrease in T levels and
nsulin sensitivity (17), possibly related to each other (18).
pproximately 25% of men with CHF have biochemical
vidence of T deficiency, and low levels have been related to
isease progression in HF (18). Relative T deficit reflects 1
spect of anabolic insufficiency that leads to a metabolic
hift favoring catabolism, a major underlying mechanism for
issue wasting seen in CHF. The prevalence of insulin
esistance in CHF and its role on CHF development have
een elucidated (19,20). Indeed, more than 40% of HF
atients, including women (21), have manifest disorders of
lucose metabolism (17); insulin resistance, leading to an
nability of insulin to promote glucose transport into skeletal
uscles, has been proposed as a mediator of skeletal muscle
atigue and wasting of CHF, linking these processes directly
o the metabolic disturbances in HF patients (22).
Our recent (10) as well as previous studies (6,8,9,23)
eported that T supplementation therapy improves exercise
apacity, insulin sensitivity, ventilatory efficiency, and mus-
le strength in elderly men with moderately severe CHF,
ven in those with normal T levels (10).
The secretion of T decreases with aging also in women
11), whereas the incidence of HF also rises in older women
s well as older men. However, no study addressed the effect
f T supplementation in elderly women with CHF.
The present study shows that low-dose T supplementa-
ion given in addition to optimal medical therapy improves
unctional capacity, insulin sensitivity, and large-muscles
trength in elderly women with CHF. The increase in
unctional capacity was related to the increase in plasma
evels of T and not related to changes in left ventricular
unction, confirming previous studies in men (8,10).
These results obtained with transdermal patch extend to
omen the findings that we (10) and others (6,8) have
eported in elderly men with CHF after T supplementation
herapy. iWe demonstrated a significant improvement—like in
en—in 6MWT, VO2, and ventilatory efficiency, all of
hich carry a negative prognosis in CHF (24). The significant
orrelation between the increase in T level and the increased
istance walked at 6MWT, a finding also reported in men
8,10), would support the hypothesis that the improvement in
unctional capacity was linked to T administration. The lack of
ny change in the P group would be consistent with this
ssumption. Testosterone supplementation improved insulin
ensitivity in women with CHF as well as in men (9,10).
This study confirms that T supplementation in women,
ike in men (10), also improves both static and dynamic
uscular performance of large, weight-bearing muscles,
hich are more relevant to the effort intolerance of the CHF
yndrome.
The improvement in 6MWT was greater in women with
ower baseline T levels. However, the improvements in
nsulin sensitivity, ventilatory efficiency, VO2, and muscular
erformances did not differ significantly between patients
ith low T levels and those with normal T levels. This
ould indicate that the benefits of T supplementation are
ot entirely confined to female CHF patients with low
aseline T, although a greater improvement in some phys-
ological parameters in the latter would be expected, similar
o what occurred in men (10).
The mechanisms through which T supplementation
ould affect cardiorespiratory parameters and insulin resis-
ance is still unclear, and this study, by its design, cannot
irectly answer to this question.
However, some tentative explanations can be advanced.
e observed a significant increase in both static and
ynamic leg performance in the testosterone-treated group.
hese effects would depend on the action of T at the
uscular level. Objective morphological and functional
bnormalities, relatively independent of reduced blood flow,
re present in the muscle of CHF patients (25) and include
ber atrophy and a prevalence of type II fibers with a
redominance of glycolytic over oxidative metabolism,
hich are involved not only in symptoms development, but
ven in the pathophysiology and worsening of the HF
yndrome, the so-called “muscle hypothesis” (3). In short,
y this hypothesis, muscle alterations occurring in CHF
ould elicit over time an enhanced muscle metaboreflex
also called “ergoreflex”) (26) activation even at moderate
evels of exercise, which in turn would be responsible for the
rolonged neurohumoral activation and abnormal cardio-
espiratory responses to exercise that characterize CHF
26–28). Interventions specifically targeted at reversing
eripheral muscle alterations, such as exercise training, have
een shown to improve muscle structure and function and
educe muscle metaboreflex overactivity and improve func-
ional capacity (25,26). The increase in leg muscle perfor-
ance observed in the present investigation after T supple-
entation, which reflects an improvement in muscle
unction, might have acted in the same manner by decreas-
ng the muscle metaboreflex overactivity.
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October 12, 2010:1310–6 Testosterone Therapy in Women With HFAnabolic administration at replacement doses has been
hown to accelerate fast- to slow-oxidative fiber type con-
ersion (29)—which is typically reduced in CHF patients
25)—and to increase the number and size of type I slow
xidative fibers (30), which implies an improved oxidative
apacity of skeletal muscles and a higher aerobic potential
ith delayed fatigue. Improved insulin sensitivity, with the
ttendant increased availability of glucose as an energy
ource for the skeletal muscle cells, might have contributed
o the reduced fatigability and might have also acted by
romoting peripheral vasodilation, resulting in an increase
n blood flow to exercising muscle.
The mechanism by which T reduces insulin resistance is
ncertain. An effect of T on muscle insulin sensitivity has
een suggested (31). Another potential mechanism would
e an action of T on visceral adipocytes metabolism
9,32,33). Uncertainty is even greater in women, because to
ur knowledge no study has addressed this issue.
We cannot compare our results with those of other
tudies, because no investigation has been performed on the
ffects of T replacement therapy in women with CHF. The
nly comparison we can draw is with studies on the effect of
supplementation in men with CHF (6,8,10): even though
doses in male studies are 10 to 20 times the replacement
oses appropriate for women, the magnitude of changes in
MWT, VO2, VE/VCO2, and MVC observed in women
n the present investigation was closely similar to that
bserved in men (6,8,10).
In our study there was high compliance, with only 2
atients discontinuing T therapy, like in the P group. This
ow percentage of dropout as compared with studies using
ransdermal patches in men with CHF (8) might be
scribed to the shorter follow-up period but mainly to the
ower rate of patches application (only twice/week). No
ndrogenic side effects were detected, confirming previous
tudies employing transdermal patches (25,34,35).
tudy limitations. Some limitations of the present inves-
igation deserve comment. The sample size was small, and
he follow-up was short, so we cannot comment on clinical
utcome. However, the present study would indicate that T
upplementation therapy improves clinical measures that
arry adverse effects and negative prognosis in CHF. In
ddition, this is a proof-of-concept study. Clinical outcome
as not the main focus of the study, and as such, any
ncertainty relating to clinical outcomes should not detract
rom the novelty of the study. Finally, T supplementation
hould be regarded at present only as an adjunctive therapy,
nd the results we obtained cannot be extrapolated at all in
ess severely ill and/or obese CHF patients. Larger long-
uration studies are needed to determine long-term efficacy
nd safety of such a replacement strategy in women with CHF.
onclusions
his proof-of-concept study indicates that T supplementa-
ion therapy improves functional capacity, insulin sensitiv-
1ty, and muscle strength in elderly female patients with
HF. The lack of effects of T on left ventricular function in
omen, like in men, seems to confirm that T acts only
hrough peripheral mechanisms.
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